CLOs on the Move

ASCENDIS PHARMA

www.ascendispharma.com

 
Ascendis Pharma is focused on creating drug candidates that are improved versions of existing drugs, yielding more effective, lower-risk drugs with new patent life. Our proprietary TransCon platform is the leading, most versatile transient conjugation technology and is utilized to create clinically superior prodrugs in therapeutic areas characterized by high unmet medical need. TransCon technology creates novel long acting prodrugs of proteins, peptides and small molecules, suitable for either local or systemic treatment. Ascendis Pharma has a diversified and balanced high-value pipeline, including internal programs and partnerships together with market leaders on their key projects.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

EBD Group

EBD Group, Inc. is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Ortonville Area Health Services

Ortonville Area Health Services is a healthcare system that includes Ortonville Hospital, Northridge Residence (nursing home), Northside Medical Clinic, Clinton Clinic, and OAHS Home Health Agency. They offer a broad scope of services to keep you and y...

PerioSeal

PerioSeal is a Little Rock, AR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MBI Solutions

MBI Solutions is a Dayton, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neuralstem

Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic